EPFL Alumni Night @ MassChallenge

Come join us for a night of innovation and networking in Boston’s Seaport!

Event Details


21 Dry Dock Avenue


December 08, 2016 from 6:00 pm to 9:00 pm America/New York (UTC-05:00)


Free, RSVP required

Come join us for a night of innovation and networking in Boston’s Seaport!

For its annual gathering the EPFL Alumni U.S. East Coast is joining forces with swissnex Boston and MassChallenge to showcase EPFL’s impressive array of innovative and global spinoffs. Four of them who have recently settled on the East Coast will pitch their venture and tell us more about their transatlantic journey, touching upon challenges and opportunities both at EPFL and in the US.

Networking and refreshments will follow at MassChallenge, with a spontaneous after party in the Seaport area.


Event program

6.00PM Doors open
6.30PM 5-minute pitches by the startups, panel discussion, and questions
7.30PM Networking and refreshments
9:00PM After party



VIVA Nutrition is a New York City-based nutrition startup that produces natural and nutritious food and supplements for children. The multicultural team from Asia, Europe, and the USA has a long experience in the industry, which allows them to bring to the table high quality nutrition, technical, regulatory, legal, sale, and marketing expertise. It is represented by its Chief Scientific Officer Riccardo Accolla, an EPFL alumnus (PhD in Neuroscience – Taste Physiology), who is a successful innovator in developing novel food formulations and then driving subsequent market adoption of healthier food products and behaviors.


Aleva Neurotherapeutics is a MedTech startup engaged in the development of the next generation of Deep Brain Stimulation systems for therapeutic application, while also eliminating technological and clinical development risks at each stage. Their first product, directSTIM (anintelligent directional electrode), has just successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland, and is being tested for long term use. It will be represented by one of its founders, Paul Pyzowski, who is deeply involved in Aleva’s strategy, business development, and US operations. Paul is an entrepreneurial, hands-on executive with a track record of transferring research and technology into early-stage companies and then developing and commercializing innovative products and services.


Anokion is a BioTech startup focused on treating autoimmune diseases by applying their antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins. Ankion will be epresented by Stephan Kontos, co-founder and vice president for research. Stephan is University of Texas at Austin graduate (chemical engineering) and an EPFL alumnus (PhD in Bioengineering) and he co-invented and developed the erythrocyte-binding tolerance technology that led to the founding of Anokion.




Nexthink is an IT startup whose mission is to help IT departments transform the way they service and support business end-users. It does this by capturing all local and network activities in real time at all endpoint in a company, instantly turning it into actionable analytics for the management. It will be represented by Marie-Lou Latrille, market research and field marketing manager, who has a strong industry background in business operations from her time at Adobe.



Seymour de Picciotto graduated from the Swiss Federal Institute of Technology in Lausanne (EPFL) with a B.S. in Life Sciences and Technology and M.S. in Bioengineering & Biotechnology. During his time on campus, he was president of Junior Entreprise EPFL, a student-run organization bridging the academic and professional world by bringing industrial projects to students, often supporting start-ups from the leman region. He then pursued his studies with a Ph.D. in Biological Engineering at MIT, where he again kept his interests on entrepreneurship close by working on the MIT 100K competition board. He also consulted for ZappRx, a specialty drug prescription management start-up based in Boston. Upon graduation, Seymour joined Moderna Therapeutics where he applies his protein engineering expertise on the development of new drugs within the New Ventures Lab group.


Event Photos